Far East Sales Commence

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Commencement of Sales in the Far East

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines, today announces that following the entering into of a licensing and distribution agreement at the end of last year with Mega Lifesciences Ltd. ("Mega"), the Company has commenced commercial operations of its first calcium soft chew product to the Far East.

A first order has been received from Mega and is being dispatched in June. This order is six months ahead of schedule and is as a result of the successful early registration of the calcium chew in Malaysia and Vietnam. Registrations in Thailand, Indonesia, Philippines, Cambodia and Myanmar continue and are expected to follow soon. The Company previously stated in an announcement released on December 15th that sales would grow to GBP250,000 per annum by the third year after launch.

In a related development, the Company has extended the distribution and licensing agreement to cover Peru, Ecuador, Ukraine, Kazak, Azerbaijan and Uzbekistan where Mega has existing operations. Mega operates in 23 countries, with a product portfolio covering segments such as Bone and Joint Health, Cardiology, Diabetes and Gastroenterology amongst others. Mega will distribute the calcium chew alongside existing product sales to the specifically identified countries.

Nigel Theobald, Chief Executive of Oxford Pharmascience Group plc commented:

"With Mega we are making great progress in the Far East. We believe this will be the first order of many and look forward to updating the market in due course on this and the continued expansion of our OXP chew technology."

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Hybridan LLP (Broker)

Claire Noyce / Deepak Reddy +44 20 7947 4350

ZAI Corporate Finance (Nominated Adviser)

John Depasquale/ John Treacy +44 20 7060 2220

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.

About Mega Lifesciences Ltd

Established 25 years ago, Mega Lifesciences is a pharmaceuticals company which operates in 23 countries.

The Company has grown to offer products in the areas of complementary medicine, herbal, pharma and OTC across segments such as such as Bone and Joint Health, Cardiology, Diabetes, Gastroenterology, Women's and Men's health, and Sports Nutrition, amongst others

ENDS